img

Global Nasal Spray Live Attenuated Influenza Vaccine Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Nasal Spray Live Attenuated Influenza Vaccine Market Insights, Forecast to 2034

The global Nasal Spray Live Attenuated Influenza Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Nasal Spray Live Attenuated Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Nasal Spray Live Attenuated Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Nasal Spray Live Attenuated Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Nasal Spray Live Attenuated Influenza Vaccine include Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, BioDiem and FluMist, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Nasal Spray Live Attenuated Influenza Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Nasal Spray Live Attenuated Influenza Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Nasal Spray Live Attenuated Influenza Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nasal Spray Live Attenuated Influenza Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Nasal Spray Live Attenuated Influenza Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Nasal Spray Live Attenuated Influenza Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, BioDiem and FluMist, etc.



By Company


Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
BioDiem
FluMist
ChangChun High & New Technology
BCHT Biotechnology
Segment by Type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine

Segment by Application


Hospital
Clinic
Public Health Agency
Other

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Nasal Spray Live Attenuated Influenza Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Nasal Spray Live Attenuated Influenza Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nasal Spray Live Attenuated Influenza Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Nasal Spray Live Attenuated Influenza Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Nasal Spray Live Attenuated Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Trivalent Flu Vaccine
1.2.3 Quadrivalent Flu Vaccine
1.3 Market by Application
1.3.1 Global Nasal Spray Live Attenuated Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Public Health Agency
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Nasal Spray Live Attenuated Influenza Vaccine Sales Estimates and Forecasts 2018-2034
2.2 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region
2.2.1 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region (2018-2024)
2.2.3 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region (2024-2034)
2.2.4 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Region (2018-2034)
2.3 Global Nasal Spray Live Attenuated Influenza Vaccine Sales Estimates and Forecasts 2018-2034
2.4 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Region
2.4.1 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Region (2018-2024)
2.4.3 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Region (2024-2034)
2.4.4 Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Manufacturers
3.1.1 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine in 2022
3.2 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Manufacturers
3.2.1 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Nasal Spray Live Attenuated Influenza Vaccine Revenue in 2022
3.3 Global Key Players of Nasal Spray Live Attenuated Influenza Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Nasal Spray Live Attenuated Influenza Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Nasal Spray Live Attenuated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Type
4.1.1 Global Nasal Spray Live Attenuated Influenza Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Nasal Spray Live Attenuated Influenza Vaccine Forecasted Sales by Type (2024-2034)
4.1.3 Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Type (2018-2034)
4.2 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type
4.2.1 Global Nasal Spray Live Attenuated Influenza Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Nasal Spray Live Attenuated Influenza Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Nasal Spray Live Attenuated Influenza Vaccine Price by Type
4.3.1 Global Nasal Spray Live Attenuated Influenza Vaccine Price by Type (2018-2024)
4.3.2 Global Nasal Spray Live Attenuated Influenza Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Application
5.1.1 Global Nasal Spray Live Attenuated Influenza Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Nasal Spray Live Attenuated Influenza Vaccine Forecasted Sales by Application (2024-2034)
5.1.3 Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Application (2018-2034)
5.2 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application
5.2.1 Global Nasal Spray Live Attenuated Influenza Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Nasal Spray Live Attenuated Influenza Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Nasal Spray Live Attenuated Influenza Vaccine Price by Application
5.3.1 Global Nasal Spray Live Attenuated Influenza Vaccine Price by Application (2018-2024)
5.3.2 Global Nasal Spray Live Attenuated Influenza Vaccine Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Market Size by Type
6.1.1 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2034)
6.1.2 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2034)
6.2 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Market Size by Application
6.2.1 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2034)
6.2.2 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2034)
6.3 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Market Size by Country
6.3.1 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2018-2034)
6.3.3 US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Nasal Spray Live Attenuated Influenza Vaccine Market Size by Type
7.1.1 Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2034)
7.1.2 Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2034)
7.2 Europe Nasal Spray Live Attenuated Influenza Vaccine Market Size by Application
7.2.1 Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2034)
7.2.2 Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2034)
7.3 Europe Nasal Spray Live Attenuated Influenza Vaccine Market Size by Country
7.3.1 Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2018-2034)
7.3.3 Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Nasal Spray Live Attenuated Influenza Vaccine Market Size
8.1.1 China Nasal Spray Live Attenuated Influenza Vaccine Sales (2018-2034)
8.1.2 China Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034)
8.2 China Nasal Spray Live Attenuated Influenza Vaccine Market Size by Application
8.2.1 China Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2034)
8.2.2 China Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Nasal Spray Live Attenuated Influenza Vaccine Market Size by Type
9.1.1 Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2034)
9.1.2 Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2034)
9.2 Asia Nasal Spray Live Attenuated Influenza Vaccine Market Size by Application
9.2.1 Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2034)
9.2.2 Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2034)
9.3 Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Region
9.3.1 Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region (2018-2034)
9.3.3 Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Sanofi Pasteur
11.1.1 Sanofi Pasteur Company Information
11.1.2 Sanofi Pasteur Overview
11.1.3 Sanofi Pasteur Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Sanofi Pasteur Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Pasteur Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 AstraZeneca Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Overview
11.3.3 CSL Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 CSL Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CSL Recent Developments
11.4 Abbott
11.4.1 Abbott Company Information
11.4.2 Abbott Overview
11.4.3 Abbott Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Abbott Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Abbott Recent Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Information
11.5.2 GlaxoSmithKline Overview
11.5.3 GlaxoSmithKline Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 GlaxoSmithKline Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 GlaxoSmithKline Recent Developments
11.6 Serum Institute
11.6.1 Serum Institute Company Information
11.6.2 Serum Institute Overview
11.6.3 Serum Institute Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Serum Institute Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Serum Institute Recent Developments
11.7 Fluenz Tetra
11.7.1 Fluenz Tetra Company Information
11.7.2 Fluenz Tetra Overview
11.7.3 Fluenz Tetra Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Fluenz Tetra Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fluenz Tetra Recent Developments
11.8 BioDiem
11.8.1 BioDiem Company Information
11.8.2 BioDiem Overview
11.8.3 BioDiem Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 BioDiem Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 BioDiem Recent Developments
11.9 FluMist
11.9.1 FluMist Company Information
11.9.2 FluMist Overview
11.9.3 FluMist Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 FluMist Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 FluMist Recent Developments
11.10 ChangChun High & New Technology
11.10.1 ChangChun High & New Technology Company Information
11.10.2 ChangChun High & New Technology Overview
11.10.3 ChangChun High & New Technology Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 ChangChun High & New Technology Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 ChangChun High & New Technology Recent Developments
11.11 BCHT Biotechnology
11.11.1 BCHT Biotechnology Company Information
11.11.2 BCHT Biotechnology Overview
11.11.3 BCHT Biotechnology Nasal Spray Live Attenuated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 BCHT Biotechnology Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 BCHT Biotechnology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Nasal Spray Live Attenuated Influenza Vaccine Industry Chain Analysis
12.2 Nasal Spray Live Attenuated Influenza Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Nasal Spray Live Attenuated Influenza Vaccine Production Mode & Process
12.4 Nasal Spray Live Attenuated Influenza Vaccine Sales and Marketing
12.4.1 Nasal Spray Live Attenuated Influenza Vaccine Sales Channels
12.4.2 Nasal Spray Live Attenuated Influenza Vaccine Distributors
12.5 Nasal Spray Live Attenuated Influenza Vaccine Customers
13 Market Dynamics
13.1 Nasal Spray Live Attenuated Influenza Vaccine Industry Trends
13.2 Nasal Spray Live Attenuated Influenza Vaccine Market Drivers
13.3 Nasal Spray Live Attenuated Influenza Vaccine Market Challenges
13.4 Nasal Spray Live Attenuated Influenza Vaccine Market Restraints
14 Key Findings in The Global Nasal Spray Live Attenuated Influenza Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Nasal Spray Live Attenuated Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Trivalent Flu Vaccine
Table 3. Major Manufacturers of Quadrivalent Flu Vaccine
Table 4. Global Nasal Spray Live Attenuated Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Region (2024-2034) & (K Units)
Table 13. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Manufacturers (2018-2024)
Table 17. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Nasal Spray Live Attenuated Influenza Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Nasal Spray Live Attenuated Influenza Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Nasal Spray Live Attenuated Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Nasal Spray Live Attenuated Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nasal Spray Live Attenuated Influenza Vaccine as of 2022)
Table 23. Global Key Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 28. Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2024-2034) & (K Units)
Table 29. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Type (2018-2024)
Table 30. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Type (2024-2034)
Table 31. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Type (2024-2034)
Table 35. Nasal Spray Live Attenuated Influenza Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Nasal Spray Live Attenuated Influenza Vaccine Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 38. Global Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2024-2034) & (K Units)
Table 39. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Application (2018-2024)
Table 40. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Application (2024-2034)
Table 41. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Application (2024-2034)
Table 45. Nasal Spray Live Attenuated Influenza Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Nasal Spray Live Attenuated Influenza Vaccine Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 56. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2024-2034) & (K Units)
Table 60. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 61. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2024-2034) & (K Units)
Table 62. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 65. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2024-2034) & (K Units)
Table 66. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 69. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 72. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2024-2034) & (K Units)
Table 73. China Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 74. China Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2024-2034) & (K Units)
Table 75. China Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 77. China Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 78. China Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2024-2034) & (K Units)
Table 79. China Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 82. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2024-2034) & (K Units)
Table 83. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 86. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2024-2034) & (K Units)
Table 87. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 90. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Region (2018-2024) & (K Units)
Table 93. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales by Country (2024-2034) & (K Units)
Table 107. Sanofi Pasteur Company Information
Table 108. Sanofi Pasteur Description and Major Businesses
Table 109. Sanofi Pasteur Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Sanofi Pasteur Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Sanofi Pasteur Recent Developments
Table 112. AstraZeneca Company Information
Table 113. AstraZeneca Description and Major Businesses
Table 114. AstraZeneca Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. AstraZeneca Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. AstraZeneca Recent Developments
Table 117. CSL Company Information
Table 118. CSL Description and Major Businesses
Table 119. CSL Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. CSL Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. CSL Recent Developments
Table 122. Abbott Company Information
Table 123. Abbott Description and Major Businesses
Table 124. Abbott Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Abbott Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Abbott Recent Developments
Table 127. GlaxoSmithKline Company Information
Table 128. GlaxoSmithKline Description and Major Businesses
Table 129. GlaxoSmithKline Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. GlaxoSmithKline Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. GlaxoSmithKline Recent Developments
Table 132. Serum Institute Company Information
Table 133. Serum Institute Description and Major Businesses
Table 134. Serum Institute Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Serum Institute Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Serum Institute Recent Developments
Table 137. Fluenz Tetra Company Information
Table 138. Fluenz Tetra Description and Major Businesses
Table 139. Fluenz Tetra Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Fluenz Tetra Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Fluenz Tetra Recent Developments
Table 142. BioDiem Company Information
Table 143. BioDiem Description and Major Businesses
Table 144. BioDiem Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. BioDiem Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. BioDiem Recent Developments
Table 147. FluMist Company Information
Table 148. FluMist Description and Major Businesses
Table 149. FluMist Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. FluMist Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. FluMist Recent Developments
Table 152. ChangChun High & New Technology Company Information
Table 153. ChangChun High & New Technology Description and Major Businesses
Table 154. ChangChun High & New Technology Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. ChangChun High & New Technology Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. ChangChun High & New Technology Recent Developments
Table 157. BCHT Biotechnology Company Information
Table 158. BCHT Biotechnology Description and Major Businesses
Table 159. BCHT Biotechnology Nasal Spray Live Attenuated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. BCHT Biotechnology Nasal Spray Live Attenuated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. BCHT Biotechnology Recent Developments
Table 162. Key Raw Materials Lists
Table 163. Raw Materials Key Suppliers Lists
Table 164. Nasal Spray Live Attenuated Influenza Vaccine Distributors List
Table 165. Nasal Spray Live Attenuated Influenza Vaccine Customers List
Table 166. Nasal Spray Live Attenuated Influenza Vaccine Market Trends
Table 167. Nasal Spray Live Attenuated Influenza Vaccine Market Drivers
Table 168. Nasal Spray Live Attenuated Influenza Vaccine Market Challenges
Table 169. Nasal Spray Live Attenuated Influenza Vaccine Market Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Nasal Spray Live Attenuated Influenza Vaccine Product Picture
Figure 2. Global Nasal Spray Live Attenuated Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Nasal Spray Live Attenuated Influenza Vaccine Market Share by Type in 2022 & 2034
Figure 4. Trivalent Flu Vaccine Product Picture
Figure 5. Quadrivalent Flu Vaccine Product Picture
Figure 6. Global Nasal Spray Live Attenuated Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Nasal Spray Live Attenuated Influenza Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Public Health Agency
Figure 11. Other
Figure 12. Nasal Spray Live Attenuated Influenza Vaccine Report Years Considered
Figure 13. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue 2018-2034 (US$ Million)
Figure 15. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Region (2018-2034)
Figure 17. Global Nasal Spray Live Attenuated Influenza Vaccine Sales 2018-2034 ((K Units)
Figure 18. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Region (2018-2034)
Figure 19. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales YoY (2018-2034) & (K Units)
Figure 20. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales YoY (2018-2034) & (K Units)
Figure 22. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Nasal Spray Live Attenuated Influenza Vaccine Sales YoY (2018-2034) & (K Units)
Figure 24. China Nasal Spray Live Attenuated Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Asia (excluding China) Nasal Spray Live Attenuated Influenza Vaccine Sales YoY (2018-2034) & (K Units)
Figure 26. Asia (excluding China) Nasal Spray Live Attenuated Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Nasal Spray Live Attenuated Influenza Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Nasal Spray Live Attenuated Influenza Vaccine in the World: Market Share by Nasal Spray Live Attenuated Influenza Vaccine Revenue in 2022
Figure 31. Global Nasal Spray Live Attenuated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Type (2018-2034)
Figure 33. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 34. Global Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Application (2018-2034)
Figure 35. Global Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 36. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Type (2018-2034)
Figure 37. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 38. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Application (2018-2034)
Figure 39. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 40. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 41. US & Canada Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Country (2018-2034)
Figure 42. U.S. Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Type (2018-2034)
Figure 45. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 46. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Application (2018-2034)
Figure 47. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 48. Europe Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 49. Europe Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Country (2018-2034)
Figure 50. Germany Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 51. France Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 52. U.K. Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 53. Italy Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. Russia Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. China Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Type (2018-2034)
Figure 56. China Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 57. China Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Application (2018-2034)
Figure 58. China Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 59. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Type (2018-2034)
Figure 60. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 61. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Application (2018-2034)
Figure 62. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 63. Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Region (2018-2034)
Figure 64. Asia Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Region (2018-2034)
Figure 65. Japan Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 66. South Korea Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 67. China Taiwan Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 68. Southeast Asia Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 69. India Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Type (2018-2034)
Figure 71. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales Market Share by Application (2018-2034)
Figure 73. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 75. Middle East, Africa and Latin America Nasal Spray Live Attenuated Influenza Vaccine Sales Share by Country (2018-2034)
Figure 76. Brazil Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Mexico Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 78. Turkey Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 79. Israel Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 80. GCC Countries Nasal Spray Live Attenuated Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 81. Nasal Spray Live Attenuated Influenza Vaccine Value Chain
Figure 82. Nasal Spray Live Attenuated Influenza Vaccine Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed